Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Retained Earnings (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Retained Earnings for 10 consecutive years, with -$482.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 9.99% year-over-year to -$482.6 million, compared with a TTM value of -$482.6 million through Sep 2025, down 9.99%, and an annual FY2024 reading of -$459.6 million, down 17.53% over the prior year.
  • Retained Earnings was -$482.6 million for Q3 2025 at Spero Therapeutics, down from -$475.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2000.0 in Q2 2021 and bottomed at -$482.6 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$366.5 million, with a median of -$417.7 million recorded in 2022.
  • The sharpest move saw Retained Earnings soared 100.0% in 2021, then crashed 21448600.0% in 2022.
  • Year by year, Retained Earnings stood at -$2000.0 in 2021, then crashed by 20693800.0% to -$413.9 million in 2022, then increased by 5.51% to -$391.1 million in 2023, then fell by 17.53% to -$459.6 million in 2024, then dropped by 5.0% to -$482.6 million in 2025.
  • Business Quant data shows Retained Earnings for SPRO at -$482.6 million in Q3 2025, -$475.2 million in Q2 2025, and -$473.5 million in Q1 2025.